SureSeq NGS panels for haematological and solid tumour cancers
An expanding portfolio of NGS panels for research into haematological and solid tumour cancers, as well as library preparation kits for the accurate detection of a wide range of genetic aberrations
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
SureSeq™ NGS panels have been designed in collaboration with recognised cancer experts to detect key aberrations implicated in a wide range of haematological and solid tumour cancers. More so, you can always modify each panel to what’s relevant to your research with SureSeq myPanel, our regularly updated, expert-curated library of pre-optimised cancer content. Simply mix and match the gene, exonic or intronic content you need to create an NGS cancer panel that meets your exact requirements.
SureSeq: Variant calling best practices
In this application note, Oxford Gene Technology discusses the best practices for variant calling. Variant calling is the computational process by which a laboratory identifies variants in sequencing data. As one of the first steps in many NGS data analysis pipelines, accurate variant calling is often critical to downstream analysis and interpretation. In turn, variant calling underpins many genomic applications, from helping to drive our understanding of genomics to facilitating research into hereditary diseases and cancer genomics, paving the way to the future of precision medicine. While differentiating between ‘true variants’ and ‘noise’ in sequencing data has presented an ongoing challenge in clinical research, advances in bioinformatics have fuelled increasingly accurate variant calling strategies.
